184 related articles for article (PubMed ID: 16641912)
41. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study.
Khatami A; Damber JE; Lodding P; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(3):213-7. PubMed ID: 12775279
[TBL] [Abstract][Full Text] [Related]
42. Long-term oncological outcome and risk stratification in men with high-risk prostate cancer treated with radical prostatectomy.
Yamamoto S; Kawakami S; Yonese J; Fujii Y; Urakami S; Masuda H; Numao N; Ishikawa Y; Kohno A; Fukui I
Jpn J Clin Oncol; 2012 Jun; 42(6):541-7. PubMed ID: 22457326
[TBL] [Abstract][Full Text] [Related]
43. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
44. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
[TBL] [Abstract][Full Text] [Related]
45. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
[TBL] [Abstract][Full Text] [Related]
46. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
47. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
48. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
Stephenson AJ; Kattan MW; Eastham JA; Bianco FJ; Yossepowitch O; Vickers AJ; Klein EA; Wood DP; Scardino PT
J Clin Oncol; 2009 Sep; 27(26):4300-5. PubMed ID: 19636023
[TBL] [Abstract][Full Text] [Related]
49. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers.
Noguchi M; Stamey TA; McNeal JE; Nolley R
J Urol; 2003 Aug; 170(2 Pt 1):459-63. PubMed ID: 12853799
[TBL] [Abstract][Full Text] [Related]
51. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
52. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis.
Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A
Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
54. The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome.
Pierorazio P; Desai M; McCann T; Benson M; McKiernan J
BJU Int; 2009 Jan; 103(1):38-42. PubMed ID: 18778352
[TBL] [Abstract][Full Text] [Related]
55. Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate.
Oefelein MG; Grayhack JT; McVary KT
Cancer; 1995 Dec; 76(12):2535-42. PubMed ID: 8625082
[TBL] [Abstract][Full Text] [Related]
56. Localised prostate cancer in elderly men aged 80-89 years, findings from a population-based registry.
Vatandoust S; Kichenadasse G; O'Callaghan M; Vincent AD; Kopsaftis T; Walsh S; Borg M; Karapetis CS; Moretti K
BJU Int; 2018 May; 121 Suppl 3():48-54. PubMed ID: 29603585
[TBL] [Abstract][Full Text] [Related]
57. DNA ploidy, Gleason score, pathological stage and serum PSA levels as predictors of disease-free survival in C-D1 prostatic cancer patients submitted to radical retropubic prostatectomy.
Di Silverio F; D'Eramo G; Buscarini M; Sciarra A; Casale P; Di Nicola S; Loreto A; Seccareccia F; De Vita R
Eur Urol; 1996; 30(3):316-21. PubMed ID: 8931963
[TBL] [Abstract][Full Text] [Related]
58. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
59. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
60. Individualized estimates of overdiagnosis in screen-detected prostate cancer.
Gulati R; Inoue LY; Gore JL; Katcher J; Etzioni R
J Natl Cancer Inst; 2014 Feb; 106(2):djt367. PubMed ID: 24399850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
